Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Guillain-Barre Syndrome Drugs Global Market Report 2025
Request Sample Buy Now
Global Guillain-Barre Syndrome Drugs Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Guillain-Barre Syndrome Drugs Global Market Report 2025

By Drug Class (Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange), By Treatment Type (First-Line Treatment, Adjunctive Or Supportive Treatment), By Application (Clinic, Hospital, Other Applications) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Guillain-Barre Syndrome Drugs Market Overview

• Guillain-Barre Syndrome Drugs market size has reached to $1.17 billion in 2024

• Expected to grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 7%

• Growth Driver: Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth

• Market Trend: Innovative Humanized Monoclonal Antibodies Revolutionize Guillain-Barre Syndrome Treatment

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Guillain-Barre Syndrome Drugs Market?

Guillain-Barre syndrome drugs refer to medications administered to manage the symptoms and complications of Guillain-Barre syndrome (GBS), an autoimmune disorder characterized by the immune system attacking the nervous system. These drugs are primarily aimed at modulating the peripheral immune system's activity to halt the progression of the disease and manage its symptoms.

The main types of guillain-barre syndrome drug classes include Immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication made from pooled human blood plasma that contains a high concentration of antibodies. They are used in first-line treatment and adjunctive or supportive treatments and find several applications in clinics, hospitals, and others.

Guillain-Barre Syndrome Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Guillain-Barre Syndrome Drugs Market Size 2025 And Growth Rate?

The guillain-barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services.

What Is The Guillain-Barre Syndrome Drugs Market Growth Forecast?

The guillain-barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy.

The forecast of 7.0% growth over the next five years reflects a modest reduction of 0.9% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions may burden U.S. neurology clinics by inflating costs of intravenous immunoglobulin (IVIG) therapies and nerve conduction study equipment imported from Germany and Australia, increasing acute neuropathy treatment costs and rehabilitation expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Guillain-Barre Syndrome Drugs Market Segmented?

1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange

2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment

3) By Application: Clinic, Hospital, Other Applications

Subsegments:

1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For Gbs Treatment, Monoclonal Antibodies As Part Of Ivig Treatment

2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Oral Corticosteroid Formulations

3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe), Plasmapheresis Equipment For Gbs Treatment, Centrifugal Plasma Exchange, Immunoadsorption Plasma Exchange, Autologous Plasma Exchange (Ape)

What Is Driving The Guillain-Barre Syndrome Drugs Market? Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth

The growing demand for personalized medicine is expected to propel the growth of the guillain-barre syndrome drugs market going forward. Personalized medicine refers to tailoring medical treatment to individual characteristics, such as genetics or lifestyle, to optimize effectiveness and minimize adverse effects. The growing demand for personalized medicine is driven by its potential to provide more effective treatments, advancements in genomics, increasing disease complexity, and regulatory support. Personalized medicine in Guillain-Barre syndrome (GBS) aims to tailor treatments based on individual patient profiles to improve therapeutic outcomes and reduce adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA (Food and Drug Administration), a US-based federal agency, approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Thus, the increasing demand for personalized medicine is driving the growth of the Guillain-Barre syndrome drugs industry.

Who Are The Major Players In The Global Guillain-Barre Syndrome Drugs Market?

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

What Are The Key Trends Of The Global Guillain-Barre Syndrome Drugs Market? Innovative Humanized Monoclonal Antibodies Revolutionize Guillain-Barre Syndrome Treatment

Major companies operating in the guillain-barre syndrome drugs market are developing innovative products, such as humanized monoclonal antibodies, to sustain their position in the market. A humanized monoclonal antibody is a type of antibody made in the laboratory by combining a human antibody with a small part of a mouse or rat monoclonal antibody. These antibodies are explored as potential therapies due to their ability to target specific components of the immune system involved in the pathological process of GBS (Guillan-Barre syndrome). For instance, in October 2023, Annexon Inc., a US-based clinical-stage biopharmaceutical company, announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) had granted orphan drug designation to ANX005 for GBS treatment. ANX005, a humanized monoclonal antibody, inhibits C1q to stop complement-mediated inflammation and neuronal damage early in GBS. Annexon has achieved target enrollment in a Phase 3 trial of ANX005 in GBS, with topline data expected in the first half of 2024. ANX005 aims to reduce inflammation and nerve damage by blocking C1q activity selectively in the nervous system, allowing rapid autoimmune damage cessation and muscle strength recovery in GBS patients.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market? Grifols SA Expands Plasma Supply With Strategic Acquisition Of Biotest AG

In April 2022, Grifols SA, a Spain-based pharmaceutical company, acquired Biotest AG for $1.17 billion. The acquisition of Biotest AG by Grifols is a strategic move aimed at expanding and diversifying Grifols’ plasma supply, bolstering its operations and revenues in Europe, the Middle East, and Africa. Additionally, IT facilitates collaborative efforts between Grifols and Biotest to enhance the global accessibility of plasma-derived therapies. Biotest AG is a Germany-based provider of drugs for the treatment of Guillain-Barre syndrome (GBS).

What Is The Regional Outlook For The Global Guillain-Barre Syndrome Drugs Market?

North America was the largest region in the guillain-barre syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Guillain-Barre Syndrome Drugs Market?

The guillain-barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Guillain-Barre Syndrome Drugs Industry?

The guillain-barre syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the guillain-barre syndrome drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Guillain-Barre Syndrome Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.25 billion
Revenue Forecast In 2034 $1.64 billion
Growth Rate CAGR of 7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications Subsegments: 1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For Gbs Treatment, Monoclonal Antibodies As Part Of Ivig Treatment
2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Oral Corticosteroid Formulations
3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe), Plasmapheresis Equipment For Gbs Treatment, Centrifugal Plasma Exchange, Immunoadsorption Plasma Exchange, Autologous Plasma Exchange (Ape)
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Guillain-Barre Syndrome Drugs Market Characteristics

3. Guillain-Barre Syndrome Drugs Market Trends And Strategies

4. Guillain-Barre Syndrome Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Guillain-Barre Syndrome Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Guillain-Barre Syndrome Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Guillain-Barre Syndrome Drugs Market Growth Rate Analysis

5.4. Global Guillain-Barre Syndrome Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Guillain-Barre Syndrome Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Guillain-Barre Syndrome Drugs Total Addressable Market (TAM)

6. Guillain-Barre Syndrome Drugs Market Segmentation

6.1. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immunoglobulins (IVIG)

Corticosteroids

Plasma Exchange

6.2. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

First-Line Treatment

Adjunctive Or Supportive Treatment

6.3. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Clinic

Hospital

Other Applications

6.4. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous Immunoglobulin (IVIG) Therapy

Human Normal Immunoglobulin (HNIG)

Hyperimmune Immunoglobulin Products

IVIG Formulations For GBS Treatment

Monoclonal Antibodies As Part Of IVIG Treatment

6.5. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Methylprednisolone

Prednisolone

Dexamethasone

Hydrocortisone

Betamethasone

Oral Corticosteroid Formulations

6.6. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Therapeutic Plasma Exchange (TPE)

Plasmapheresis Equipment For GBS Treatment

Centrifugal Plasma Exchange

Immunoadsorption Plasma Exchange

Autologous Plasma Exchange (APE)

7. Guillain-Barre Syndrome Drugs Market Regional And Country Analysis

7.1. Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Guillain-Barre Syndrome Drugs Market

8.1. Asia-Pacific Guillain-Barre Syndrome Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Guillain-Barre Syndrome Drugs Market

9.1. China Guillain-Barre Syndrome Drugs Market Overview

9.2. China Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Guillain-Barre Syndrome Drugs Market

10.1. India Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Guillain-Barre Syndrome Drugs Market

11.1. Japan Guillain-Barre Syndrome Drugs Market Overview

11.2. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Guillain-Barre Syndrome Drugs Market

12.1. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Guillain-Barre Syndrome Drugs Market

13.1. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Guillain-Barre Syndrome Drugs Market

14.1. South Korea Guillain-Barre Syndrome Drugs Market Overview

14.2. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Guillain-Barre Syndrome Drugs Market

15.1. Western Europe Guillain-Barre Syndrome Drugs Market Overview

15.2. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Guillain-Barre Syndrome Drugs Market

16.1. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Guillain-Barre Syndrome Drugs Market

17.1. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Guillain-Barre Syndrome Drugs Market

18.1. France Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Guillain-Barre Syndrome Drugs Market

19.1. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Guillain-Barre Syndrome Drugs Market

20.1. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Guillain-Barre Syndrome Drugs Market

21.1. Eastern Europe Guillain-Barre Syndrome Drugs Market Overview

21.2. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Guillain-Barre Syndrome Drugs Market

22.1. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Guillain-Barre Syndrome Drugs Market

23.1. North America Guillain-Barre Syndrome Drugs Market Overview

23.2. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Guillain-Barre Syndrome Drugs Market

24.1. USA Guillain-Barre Syndrome Drugs Market Overview

24.2. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Guillain-Barre Syndrome Drugs Market

25.1. Canada Guillain-Barre Syndrome Drugs Market Overview

25.2. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Guillain-Barre Syndrome Drugs Market

26.1. South America Guillain-Barre Syndrome Drugs Market Overview

26.2. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Guillain-Barre Syndrome Drugs Market

27.1. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Guillain-Barre Syndrome Drugs Market

28.1. Middle East Guillain-Barre Syndrome Drugs Market Overview

28.2. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Guillain-Barre Syndrome Drugs Market

29.1. Africa Guillain-Barre Syndrome Drugs Market Overview

29.2. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Guillain-Barre Syndrome Drugs Market Competitive Landscape And Company Profiles

30.1. Guillain-Barre Syndrome Drugs Market Competitive Landscape

30.2. Guillain-Barre Syndrome Drugs Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Guillain-Barre Syndrome Drugs Market Other Major And Innovative Companies

31.1. Biogen Inc.

31.2. Chugai Pharmaceutical Co. Ltd.

31.3. Grifols SA

31.4. Octapharma AG

31.5. Cadila Healthcare Limited

31.6. Argenx SE

31.7. Alnylam Pharmaceuticals Inc.

31.8. Biotest AG

31.9. CSL Behring LLC

31.10. Kedrion Biopharma Inc.

31.11. Cellenkos Inc.

31.12. Annexon Inc.

31.13. Hansa Medical AB

31.14. Akari Therapeutics Plc

31.15. Alexion Pharmaceuticals Inc.

32. Global Guillain-Barre Syndrome Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market

34. Recent Developments In The Guillain-Barre Syndrome Drugs Market

35. Guillain-Barre Syndrome Drugs Market High Potential Countries, Segments and Strategies

35.1 Guillain-Barre Syndrome Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Guillain-Barre Syndrome Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Guillain-Barre Syndrome Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 78: Merck & Co. Inc. Financial Performance
  • Table 79: AbbVie Inc. Financial Performance
  • Table 80: Novartis AG Financial Performance
  • Table 81: Takeda Pharmaceutical Company Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 78: Merck & Co. Inc. Financial Performance
  • Figure 79: AbbVie Inc. Financial Performance
  • Figure 80: Novartis AG Financial Performance
  • Figure 81: Takeda Pharmaceutical Company Limited Financial Performance

In-Depth Skin Booster Market Report: Business Trends, Growth Factors, and Forecast to 2029

Read More About In-Depth Skin Booster Market Report: Business Trends, Growth Factors, and Forecast to 2029

2025 Analysis: Opportunities and Risks in the Evolving STAY-C For Feed Market

Read More About 2025 Analysis: Opportunities and Risks in the Evolving STAY-C For Feed Market

Global Insights: Sustained Release Excipients Market Expected to Surpass $2.1 Billion by 2029

Read More About Global Insights: Sustained Release Excipients Market Expected to Surpass $2.1 Billion by 2029

2025 Thalassemia Drugs Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Thalassemia Drugs Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route O...

View Report

Terminal Tractor Global Market Report 2025 – By Type (Manual, Automated), By Propulsion (Diesel, Compressed Natural Gas (CNG), Hybrid, Electric), By Tonnage (Less Than 50 Ton, 50-100 Ton, Greater Than 100 Ton), By Axle (...

View Report

Glass Substrate Global Market Report 2025 – By Type (Borosilicate Based, Fused Silica And Quartz Based, Silicon, Other Types), By Wafer Diameter (300 mm, 200 mm, 150 mm, 125 mm, Above 300 mm, Upto 100 mm), By Application...

View Report

Pharmaceutical Suppositories Global Market Report 2025 – By Type (Rectal Suppositories, Vaginal Suppositories, Urethral Suppositories, Other Types), By Base (Fatty Base, Water Miscible Bases, Emulsifying Bases), By End-U...

View Report

Flexion Tires Global Market Report 2025 – By Type (Summer Tires, Winter Tires, All-Season Tires), By Vehicle Type ( Passenger Cars, Light Commercial Vehicles, Heavy Commercial Vehicles), By Sales Channel (Original Equipm...

View Report

Onshore Wind Turbine Global Market Report 2025 – By Axis (Horizontal Axis, Vertical Axis), By Size (Small Scale, Medium Scale, Large Scale), By Technology (Electrically Excited Synchronous Generator, Permanent Magnet Syn...

View Report

Frequently Asked Questions

Guillain-Barre syndrome drugs refer to medications administered to manage the symptoms and complications of Guillain-Barre syndrome (GBS), an autoimmune disorder characterized by the immune system attacking the nervous system. These drugs are primarily aimed at modulating the peripheral immune system's activity to halt the progression of the disease and manage its symptoms. For further insights on this market, request a sample here

The market major growth driver - Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth. For further insights on this market, request a sample here

The guillain-barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services. The guillain-barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to " $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy. For further insights on this market, request a sample here

The guillain-barre syndrome drugs market covered in this report is segmented –
1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications Subsegments:
1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For Gbs Treatment, Monoclonal Antibodies As Part Of Ivig Treatment
2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Oral Corticosteroid Formulations
3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe), Plasmapheresis Equipment For Gbs Treatment, Centrifugal Plasma Exchange, Immunoadsorption Plasma Exchange, Autologous Plasma Exchange (Ape) For further insights on this market, request a sample here

North America was the largest region in the guillain-barre syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc . For further insights on this market, request a sample here.

Major trends in this market include Innovative Humanized Monoclonal Antibodies Revolutionize Guillain-Barre Syndrome Treatment. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Guillain-Barre Syndrome Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon